A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors
This is a prospective, open, phase I clinical study to evaluate the safety and tolerability of a CDK4 / 6 inhibitor and a MEK inhibitor in the treatment of metastatic digestive system tumors
Digestive System Tumors
DRUG: a CDK4 / 6 inhibitor and a MEK inhibitor
To determine the maximum tolerated dose of a CDK4 / 6 inhibitor and a MEK inhibitor therapy, Up to approximately 24 months
ORR, the Objective Remission Rate, Up to approximately 24 months
This is a prospective, open, phase I clinical study to evaluate the safety and tolerability of a CDK4 / 6 inhibitor and a MEK inhibitor in the treatment of metastatic digestive system tumors